Cargando…
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond
While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. This is important as clinical decisions may vary depending on which imagi...
Autores principales: | Hildebrandt, Malene Grubbe, Lauridsen, Jeppe Faurholdt, Vogsen, Marianne, Holm, Jorun, Vilstrup, Mie Holm, Braad, Poul-Erik, Gerke, Oke, Thomassen, Mads, Ewertz, Marianne, Høilund-Carlsen, Poul Flemming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721531/ https://www.ncbi.nlm.nih.gov/pubmed/31443324 http://dx.doi.org/10.3390/cancers11081190 |
Ejemplares similares
-
Group-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study
por: Gerke, Oke, et al.
Publicado: (2017) -
FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review
por: Helland, Fredrik, et al.
Publicado: (2019) -
Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer
por: Sørensen, Jonas S., et al.
Publicado: (2020) -
Prognostic Value of Dual-Time-Point (18)F-Fluorodeoxyglucose PET/CT in Metastatic Breast Cancer: An Exploratory Study of Quantitative Measures
por: Naghavi-Behzad, Mohammad, et al.
Publicado: (2020) -
Perspective of Patients With Metastatic Breast Cancer on Electronic Access to Scan Results: Mixed Methods Study
por: Baun, Christina, et al.
Publicado: (2020)